• LAST PRICE
    28.3500
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    27.2800/ 3
  • Ask / Lots
    29.1900/ 1
  • Open / Previous Close
    0.0000 / 28.3500
  • Day Range
    ---
  • 52 Week Range
    Low 21.2400
    High 33.0000
  • Volume
    ---
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table
TimeVolumeALKS
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesALKS
Alkermes Plc
4.6B
-74.5x
---
United StatesMEDP
Medpace Holdings Inc
4.5B
24.9x
+67.16%
United StatesNVAX
Novavax Inc
3.6B
-2.6x
---
United StatesCRSP
CRISPR Therapeutics AG
4.1B
14.5x
---
United StatesIONS
Ionis Pharmaceuticals Inc
5.3B
-1,344.1x
---
United StatesVIR
Vir Biotechnology Inc
3.0B
2.5x
---
As of 2022-05-25

Company Information

Alkermes Public Limited Company is a fully integrated biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. It has a portfolio of commercial products focused on addiction, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurodegenerative disorders and cancer. The Company's products include ALKERMES, ARISTADA, ARISTADA INITIO, LinkeRx, LYBALVI, NanoCrystal and VIVITROL. Its other trademark includes INVEGA SUSTENNA, INVEGA TRINZA, TREVICTA, XEPLION, and RISPERDAL CONSTA, KEYTRUDA and VUMERITY. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.

Contact Information

Headquarters
Connaught HSE, 1 Burlington RoadDUBLIN, Ireland 00000
Phone
---
Fax
---

Executives

Chairman of the Board, Chief Executive Officer
Richard Pops
Chief Financial Officer, Senior Vice President
Iain Brown
Chief Operating Officer, Executive Vice President
Blair Jackson
Executive Vice President, Research and Development and Chief Medical Officer
Craig Hopkinson
Senior Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
David Gaffin

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$4.6B
Revenue (TTM)
$1.2B
Shares Outstanding
163.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.74
EPS
$-0.38
Book Value
$6.87
P/E Ratio
-74.5x
Price/Sales (TTM)
3.9
Price/Cash Flow (TTM)
279.9x
Operating Margin
-3.28%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.